A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors Ye Guo (Shanghai, China) 162MO | Mini Oral session: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback